Tier 4 — mechanistic

The anti-diabetic potential of betaine. Mechanisms of action in rodent models of type 2 diabetes

Katarzyna Szkudelska, Tomasz Szkudelski
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2022 150:112946

Bibliography

PubMed
PMID 35413601
DOI
10.1016/j.biopha.2022.112946
Funding
Funding was not specified in the indexed record or accessible funding metadata.
Competing interests
A competing-interest declaration was not available in the indexed record or accessible disclosure metadata.

Study snapshot

DesignNarrative review
ModelEvidence synthesis; mixed research models
SamplePublished literature; no newly enrolled participant cohort
InterventionReview of betaine-related evidence; no single assigned intervention
DurationEvidence review; source-specific study durations vary
EndpointsBetaine biology; Clinical and mechanistic evidence

What the study showed, in plain terms

Published in 2022, this source examined mechanistic and clinical reviews. Its evidence base was Published literature; no newly enrolled participant cohort. It evaluated Review of betaine-related evidence; no single assigned intervention across Evidence review; source-specific study durations vary.

Reviews glucose, insulin-signaling and stress-response effects reported in rodent diabetes models.

The article concerns rodent mechanisms, and human prediabetes trials have not reproduced broad metabolic benefit.

Continue with TMG Data Center

Continue with TMG for Weight Loss: Body-Fat Findings and Their Limits

Key findings

  • Reviews glucose, insulin-signaling and stress-response effects reported in rodent diabetes models.
  • The recorded outcome domains were Betaine biology; Clinical and mechanistic evidence.

What this study can and cannot tell us

  • The article concerns rodent mechanisms, and human prediabetes trials have not reproduced broad metabolic benefit.
  • The conclusions inherit the limitations of the underlying studies. A narrative interpretation or guideline recommendation is not a new randomized treatment comparison.
  • Source basis: Indexed abstract and bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 4
Dietary Choline and Betaine Are Not Associated With the Risk of Type 2 Diabetes. A Systematic Review and Meta-Analysis of Observational Studies
Elham Sharifi-Zahabi et al. · Journal of diabetes research · 2026
Tier 2
Metabolic Effects of Betaine: A Randomized Clinical Trial of Betaine Supplementation in Prediabetes
Ana Maria Grizales et al. · The Journal of clinical endocrinology and metabolism · 2018
Tier 4
High Betaine, a Trimethylamine N-Oxide Related Metabolite, Is Prospectively Associated with Low Future Risk of Type 2 Diabetes Mellitus in the PREVEND Study
Erwin Garcia et al. · Journal of clinical medicine · 2019
Tier 4
Associations between Serum Betaine, Methyl-Metabolizing Genetic Polymorphisms and Risk of Incident Type 2 Diabetes: A Prospective Cohort Study in Community-Dwelling Chinese Adults
Xiaoting Lu et al. · Nutrients · 2022
Tier 4
Decoding Betaine: A Critical Analysis of Therapeutic Potential Compared with Marketing Hype-A Narrative Review
Grzegorz Nikrandt et al. · The Journal of nutrition · 2024
Tier 4
Beneficial Effects of Betaine: A Comprehensive Review
Madan Kumar Arumugam et al. · Biology · 2021

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology